Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate.
about
The Rab27a-binding protein, JFC1, regulates androgen-dependent secretion of prostate-specific antigen and prostatic-specific acid phosphataseIdentification of androgen-coregulated protein networks from the microsomes of human prostate cancer cellsOestrogens and oestrogen receptors in prostate cancerSurgery and hormonal treatment for prostate cancer and sexual functionMechanisms of resistance in castration-resistant prostate cancer (CRPC)Prostate cancer stem cells: the role of androgen and estrogen receptorsTargeting molecular resistance in castration-resistant prostate cancerCardiovascular effects of hormone therapy for prostate cancerNew drugs for prostate cancerQuality of life issues in men undergoing androgen deprivation therapy: a reviewRationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancerMale pattern baldness in relation to prostate cancer risks: an analysis in the VITamins and lifestyle (VITAL) cohort study.Testosterone therapy in men with testosterone deficiency: Are we beyond the point of no return?Oxidative stress in prostate cancer patients: A systematic review of case control studiesStroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic reviewEstrogen-Related Receptors in Breast Cancer and Prostate CancerMetabolomic profiling reveals a role for androgen in activating amino acid metabolism and methylation in prostate cancer cellsProstatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epitheliumA Rat α-Fetoprotein Binding Activity Prediction Model to Facilitate Assessment of the Endocrine Disruption Potential of Environmental ChemicalsCancer treatment-related bone disease.Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma.The isolation and identification of apolipoprotein C-I in hormone-refractory prostate cancer using surface-enhanced laser desorption/ionization time-of-flight mass spectrometryEstradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer.Stromal transforming growth factor-beta signaling mediates prostatic response to androgen ablation by paracrine Wnt activityGlucocorticoids and prostate cancer treatment: friend or foe?Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden.Drug costs in the management of metastatic castration-resistant prostate cancer in Canada.Genistein increases epidermal growth factor receptor signaling and promotes tumor progression in advanced human prostate cancerAndrographolide targets androgen receptor pathway in castration-resistant prostate cancer.A history of prostate cancer treatmentPreclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint.Human prostatic acid phosphatase, an authentic tyrosine phosphatase, dephosphorylates ErbB-2 and regulates prostate cancer cell growthEffects of in utero exposure to Bisphenol A or diethylstilbestrol on the adult male reproductive system.Cardiac and cognitive effects of androgen deprivation therapy: are they real?Crosstalk between nuclear MET and SOX9/β-catenin correlates with castration-resistant prostate cancerAndrogen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies.Neoplastic reprogramming of patient-derived adipose stem cells by prostate cancer cell-associated exosomes.National practice patterns and time trends in androgen ablation for localized prostate cancer.Metastatic castration-resistant prostate cancer: critical review of enzalutamide.
P2860
Q24537168-02573928-FC99-42F2-B018-CC2C96C1080CQ24806811-32EB98AB-6D60-4353-A53A-78DE124D791DQ26749122-5C5CC2F4-4356-445D-AA19-26C05B1FAC21Q26773774-056BE92A-4199-47FC-885C-ACD132461771Q26774221-58AEBA02-4B33-4D0E-AAEB-4BF2C49B7DA3Q26778415-52561FB7-6863-4F1A-B995-CCDC056313CFQ26795445-C4DECBE0-D10C-44D5-8BD7-8888FF032EDEQ26801112-65EFFACF-852F-4DD1-891F-7CE690243E49Q26827515-AFBAAFC4-96DA-4E40-BC69-B28231389014Q27002887-B4DE4E88-6BE7-43B2-B600-22DDAF5E5F5AQ27028084-7F298AD2-8BAF-45FC-A0DA-B6BF5FA1412BQ27331357-20FEFF6B-D61D-45B3-A8E1-2D8F277C42B3Q28068397-134DB50B-C2A4-4A40-BE8F-6EADFE39A690Q28068523-9683C2AB-8806-4E99-8F2B-FD3164DA37CCQ28069320-A360F216-7FF4-429D-BD00-214B534A641EQ28084030-9DC8AD69-6B05-4BB6-B278-A89F3025D95CQ28479062-FFA0E7C8-D092-481E-8FC1-9268448BF086Q28508802-21B41F3B-20AE-488D-B3CA-9DFE2776DA0CQ28834111-9FDAA35F-BF7C-48A8-8F3D-785FA0C3470FQ30438185-3EAF5553-01EA-429A-94F9-841E530153C9Q30495758-6B435067-D142-41E2-86C2-82A32C999AE6Q30686407-6A4A6760-1117-4A6E-8843-C41661A5F768Q33404355-927DDB51-F95C-4FD9-8BE6-E0C0FCEE4AE8Q33590201-9DA7F68B-B742-49CA-B017-C775FEE2AEC5Q33611142-1418B81F-9EBD-43A6-AE28-EAAC8EF33E45Q33621387-689529B0-9599-496C-96A6-3EF8641D24C1Q33819138-31ED42B6-F208-4B10-8A8A-21CB5915E6A6Q33904772-F19DDF14-75CC-4A54-B70F-5FC94D99BB3DQ33908395-AA25F77C-4552-4FFE-809A-8F8C31226A56Q33968384-E6E7198A-AE13-446A-8FD4-B4DBF6DC82AAQ34013878-69539682-63BB-4228-BBEC-62FD4D10526FQ34013882-F9EC9B41-AD0B-42ED-AA1F-BDACCEC800AEQ34025197-E3D49CAB-5649-4C61-91DF-79B3E08A2596Q34028574-384E1631-52B8-4A9E-92A9-AF0406989FBCQ34111628-81924A89-799E-4EB4-A4E2-C9C87DB1FDFCQ34265065-89851749-A3A6-49E6-8166-16E200E94AC1Q34267991-CB43C122-5C93-4B32-96B9-575690F47CB9Q34285282-59105FD5-1C34-4813-9DDE-8638076158F3Q34363769-F8D7344A-39DA-4B41-A080-60B3617B7815Q34381852-D7931F20-5414-495A-9E0C-4E6CBDC2809F
P2860
Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate.
description
1972 nî lūn-bûn
@nan
1972 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1972 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1972年の論文
@ja
1972年論文
@yue
1972年論文
@zh-hant
1972年論文
@zh-hk
1972年論文
@zh-mo
1972年論文
@zh-tw
1972年论文
@wuu
name
Studies on prostatic cancer. I ...... tic carcinoma of the prostate.
@ast
Studies on prostatic cancer. I ...... tic carcinoma of the prostate.
@en
Studies on prostatic cancer. I ...... tic carcinoma of the prostate.
@nl
type
label
Studies on prostatic cancer. I ...... tic carcinoma of the prostate.
@ast
Studies on prostatic cancer. I ...... tic carcinoma of the prostate.
@en
Studies on prostatic cancer. I ...... tic carcinoma of the prostate.
@nl
prefLabel
Studies on prostatic cancer. I ...... tic carcinoma of the prostate.
@ast
Studies on prostatic cancer. I ...... tic carcinoma of the prostate.
@en
Studies on prostatic cancer. I ...... tic carcinoma of the prostate.
@nl
P1433
P1476
Studies on prostatic cancer. I ...... tic carcinoma of the prostate.
@en
P2093
P304
P356
10.3322/CANJCLIN.22.4.232
P407
P577
1972-07-01T00:00:00Z